Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04382547

Enrollment

Registered

2020-05-11

Start date

2020-05-11

Completion date

2021-06-30

Last updated

2021-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, Covid-19, Coronavirus, Pneumonia, Pneumonia, Viral, Pneumonia, Interstitial, Sars-CoV2

Keywords

pneumonia, Sars-COV2, Covid-19

Brief summary

Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Detailed description

During the implementation of the project, it is planned to develop a method for the treatment of severe covid-19 associated interstitial pneumonia using allogeneic mesenchymal stem cells. The positive outlook for the effectiveness of MSCs is due to the following: * knowledge of the leading role of immunopathogenetic mechanisms in the development of acute interstitial lung diseases and the pronounced immunomodulating properties of MSCs; * high tropism of MSCs to lung tissue when administered intravenously; * the ability of MSCs to stimulate tissue regeneration and the effective use of MSCs in the treatment of acute damage to the myocardium and kidneys, which will contribute to the treatment of multiple organ failure; * positive results of preclinical studies of the method of treatment of viral pneumonia in animals, and the first clinical studies in patients.

Interventions

BIOLOGICALAllogenic pooled olfactory mucosa-derived mesenchymal stem cells

Allogenic pooled olfactory mucosa-derived mesenchymal stem cells

OTHERStandard treatment according to the Clinical protocols

Standard treatment according to the Clinical protocols

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* PCR-confirmed Covid-19 pneumonia * respiratory failure

Exclusion criteria

* diagnosed cancer

Design outcomes

Primary

Measure	Time frame	Description
Number of cured patients	3 weeks	Number of patients cured, assessed by PCR in addition to chest CT scan

Secondary

Measure	Time frame	Description
Number of patients with treatment-related adverse events	3 weeks	MSC infusion related adverse events assessed by blood count, liver and function tests

Countries

Belarus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026